KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Equity Average (2016 - 2025)

Historic Equity Average for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Q3 2025 value amounting to $99.8 million.

  • Rigel Pharmaceuticals' Equity Average rose 54790.8% to $99.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.8 million, marking a year-over-year increase of 54790.8%. This contributed to the annual value of -$12.7 million for FY2024, which is 4000.0% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Equity Average stood at $99.8 million, which was up 54790.8% from $50.3 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Equity Average registered a high of $99.8 million during Q3 2025, and its lowest value of -$30.8 million during Q2 2024.
  • Over the past 5 years, Rigel Pharmaceuticals' median Equity Average value was -$5.7 million (recorded in 2024), while the average stood at $9.8 million.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Equity Average tumbled by 177805.19% in 2023, and later soared by 54790.8% in 2025.
  • Rigel Pharmaceuticals' Equity Average (Quarter) stood at $40.0 million in 2021, then plummeted by 141.79% to -$16.7 million in 2022, then plummeted by 80.8% to -$30.2 million in 2023, then surged by 81.24% to -$5.7 million in 2024, then skyrocketed by 1858.4% to $99.8 million in 2025.
  • Its Equity Average stands at $99.8 million for Q3 2025, versus $50.3 million for Q2 2025 and $10.9 million for Q1 2025.